The Leukemia & Lymphoma Society (LLS) will present new data from its Beat AML Master Clinical Trial and Pediatric Acute ...
Study reveals how socioeconomic factors create barriers to bone marrow transplants for AML patients in disadvantaged ...
The first comprehensive map of the dramatic changes that take place in the blood system over the course of the human lifetime could have implications for the treatment of acute myeloid leukemia and ...
Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.
Medically reviewed by Doru Paul, MD Leukemia is a cancer that changes blood cells. It usually develops in the bone marrow, the inner part of the bone that makes immature cells that eventually develop ...
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting ...
Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced positive preclinical data on ...
8, 2024 — Patients with acute myeloid leukemia who have lower education and income are less likely to receive ... treat and cure cancer and infectious diseases worldwide. Based in Seattle, Fred Hutch ...
Phase 2 data show about half of patients with high-risk or secondary acute myeloid leukemia achieved a complete response or ...
Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 7-10. Improving access to life-saving therapies for blood disorders is the theme ...
A subset of patients with myeloproliferative neoplasms (MPNs) -- clonal disorders of hematopoietic stem cells that include ...
Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today presented positive long-term data on its lead investigational ...